A long-running research-compound vendor is winding down on July 1, 2026 — and the timing says as much about the industry as it does about the company.

Strate Labs, a long-running supplier of research peptides, SARMs, and related compounds, is winding down. The company’s storefronts are now carrying a sitewide notice that it is closing on July 1, 2026, paired with clearance discounts across its catalog. For a vendor that marketed itself as a decade-old fixture in the space, the announcement is notable — and it lands in the middle of one of the most active enforcement periods the research-use-only (RUO) peptide market has seen.

This post lays out what is publicly known about the closure, the legal case that preceded it, and the broader regulatory backdrop that is reshaping how RUO suppliers operate. The aim here is to report the situation neutrally, not to celebrate or condemn it. If you research or source compounds in this category, understanding the forces at work matters more than the fate of any single vendor.

What’s actually happening with Strate Labs

The most concrete signal is on Strate Labs’ own site: a banner announcing a July 1 shutdown with everything-must-go pricing, including discounts on its higher-demand items. The company has historically sold a broad mix of formats — peptides, oral capsules, topical blends, and SARMs — across parallel domains, with publicly posted batch- and lot-coded Certificates of Analysis (COAs) and tamper-evident packaging.

Strate Labs has not, as of this writing, published a detailed public explanation for the wind-down. That absence of a stated reason is itself a pattern in this market: several closures over the past year have arrived as terse “voluntary” notices with little elaboration. If you’ve followed the difference between transparent and opaque operations, our breakdown of underground and grey-market peptide sources covers why that distinction matters. What sets Strate Labs apart is that there is a clear, documented legal thread leading up to it.

The Eli Lilly ITC case behind the exit

In March 2024, Eli Lilly filed a complaint with the U.S. International Trade Commission (ITC) targeting roughly a dozen vendors it accused of importing and selling tirzepatide — the active compound in Lilly’s Mounjaro and Zepbound — in ways that infringed its trademark or amounted to false designation of origin. Strate Labs was one of the named respondents.

In May 2024, Strate Labs and several other vendors were found in default after not adequately participating in the proceeding. The case concluded in early 2025 with a layered remedy documented in the Federal Register:

• A General Exclusion Order (GEO) blocking the importation of tirzepatide products that infringe Lilly’s trademark or carry a false designation of origin — an order that applies broadly, not just to the named parties.
• Limited Exclusion Orders against specific respondents.
• Cease and Desist Orders (CDOs) directed at a short list of vendors, including Strate Labs.

A cease-and-desist order from the ITC is a meaningful piece of legal exposure for any vendor that continues to handle the affected compounds. While Strate Labs has not framed its closure as a direct consequence of that order, the sequence — default judgment, exclusion and cease-and-desist orders, then a wind-down announcement — is hard to read in isolation from the litigation.

The bigger picture: mounting pressure on RUO suppliers

Strate Labs is not closing in a vacuum. The RUO peptide segment has been absorbing escalating pressure from several directions at once, and the cumulative effect is changing who can realistically operate.

The shortage exemption ended. When the FDA declared the semaglutide and tirzepatide shortages resolved in 2025, it removed the regulatory exemption that had allowed compounding pharmacies to produce those drugs during scarcity. That collapsed one of the channels the grey market had been adjacent to, and it concentrated regulatory attention on everything still selling GLP-1-class metabolic compounds.

The FDA stepped up enforcement. In September 2025, the agency issued more than 50 warning letters tied to compounded GLP-1 products marketed as generic equivalents or with comparative claims to approved drugs. It also established an import alert aimed at stopping GLP-1 active ingredients with quality concerns from entering the country. Separately, several research-channel vendors have been named in FDA warning letters, and at least one operation saw its warehouse raided in mid-2025.

State attorneys general entered the gap. Legal analysts have noted that state AGs are increasingly using consumer-protection law to pursue sellers who market compounds as “research only” while effectively guiding buyers toward human use. That theory of enforcement doesn’t depend on FDA action and widens the field of potential exposure considerably.

Quality data is under scrutiny. Third-party testing has put a spotlight on certain compounds. Reporting on the recent wave of shutdowns has highlighted retatrutide in particular, where a sizable batch of independently tested samples reportedly received failing purity grades — the kind of data that fuels both regulatory interest and buyer skepticism, and that underscores why batch-level COAs matter.

The rules themselves are in motion. The picture isn’t uniformly tightening. HHS leadership has signaled interest in expanding compounding access, and some peptides were returned to a bulk-substances category that allows compounding. An FDA advisory panel scheduled for mid-2026 is expected to review several peptide molecules. In other words, the framework is still being actively rewritten, and the next 12 to 18 months are likely to bring more change rather than settled clarity.

What it means for the RUO market

A reasonable read of the current environment is that it is separating vendors into two groups. On one side are operations that openly featured patented, prescription-equivalent compounds — especially GLP-1 agonists — without much compliance infrastructure. On the other are suppliers that maintain genuine research-use positioning, keep batch-specific COA documentation, rely on independent third-party testing, and avoid marketing that implies human consumption.

The enforcement wave is, in practical terms, harder on the first group. Vendors carrying active litigation, ignored warning letters, or quality failures are the ones most likely to exit — voluntarily or otherwise. Strate Labs, with a documented ITC default and cease-and-desist order on the record, fits that profile.

For researchers and buyers, the takeaway is less about any one brand disappearing and more about a structural shift. Pending orders, warranty on stock, and COA access can all become uncertain when a vendor winds down quickly, so it’s worth understanding a supplier’s standing before committing. Compounds sold under the RUO designation are intended strictly for laboratory and research purposes and are not approved for human use; that distinction is central both to how this market is regulated and to how the current enforcement is being framed.

Frequently asked questions

The bottom line

Strate Labs’ closure is one data point in a much larger realignment. The combination of pharmaceutical litigation, resolved drug shortages, FDA enforcement, state-level action, and quality scrutiny has narrowed the operating space for RUO peptide suppliers considerably. Whether the regulatory framework ultimately tightens further or loosens in places remains genuinely unsettled. For now, the clearest signal is that documentation, testing, and disciplined RUO positioning are becoming the dividing line between vendors that continue and those that don’t.